Eva McLellan

Building and leading a high-performing global leadership team across Access Strategy, Medical, Marketing, and Commercial Operations, spanning the U.S. and Pharma International Markets. We are committed to delivering best-in-class health innovations for individuals living with metabolic and obesity-related diseases, transforming the trajectory of human health. Our mandate is end-to-end: shaping development and commercial priorities across the disease area to maximize portfolio impact What energizes me about this role is the chance to shape a category, to build the team, the strategy, and the operating system that turn ambitious science into outcomes patients can feel.

Country CEO & P&L owner. Proudly advancing Roche’s innovation ambition for patients and society, I focused on building a sustainable, high-performing organization anchored in people, while forging strong external partnerships that measurably shaped health systems and improved access to innovative medicines and diagnostics. I held full legal accountability for both Roche Pharma and Roche Diagnostics, leading an organisation of 90 talented colleagues. In addition to my role as General Manager, I sponsored and co-led the Commercial Task Force for Ophthalmology across 23 European countries, stewarding commercialization strategy and execution. Within two years, we successfully expanded access and achieved high growth in more than 15 markets, accelerating the delivery of life-changing therapies to patients. Strong external affairs experience, strengthening reputation leadership, and driving meaningful public–private engagement: - Vice President of the Board, Am Cham 2024-2025 - Board Member, Am Cham Slovenia 2023-2024 - Co-Chair, Bled Institute for Leadership in Digitisation and AI (BILDAI), IEDC 2023-2025

Member of the Belgium & Luxembourg Pharma Executive Board. Accountable for P&L~ 300m and leadership of the commercial portfolio, driving outcomes focused on patient and business value across our entire portfolio. Led 13 commercial business leaders and a 50+ person matrix organization spanning Product Strategy, Digital, Insights and PHC/Innovation. In addition, I served as the Chief Transformation Officer (CTO), responsible for architecting and executing on company wide transformation of our business strategy, structure and culture transformation vision, with the goal of inspiring and enabling our people to deliver better outcomes for more patients, faster. Under my leadership, we launched multiple high-impact medicines from the Roche portfolio, extending essential care to more than 13,000 patients in Belgium. During one of the most challenging public health crises of our time, my team and I demonstrated the value of a collaborative approach by seamlessly integrating technology, diagnostics, and treatments to ensure continuity in essential care.

As a key member of both the Region Europe Commercial team and the Global Product Strategy (GPS), Signaling & Hematology Franchise Leadership Team, I played a pivotal role in steering the commercial leadership for the Oncology Pipeline Portfolio globally. Responsible for leading the integrated development, commercialization, pricing/access strategy, and launch planning of Immuno-Oncology and Hematology assets. I successfully directed efforts in five major EU markets along with Canada and Nordics resulting in commercial success at launch. My commercials leadership extended to building a team and leading a team overseeing the European integrated plan, decision alignment, and commercial recommendations, including the pricing/access strategy for significant assets such as Hemlibra, Polivy, Ipatasertib, Tecentriq combinations in GI/GU, Breast, and Lung, as well as CD20-TCB assets.

Selected to design a new patient-centric, go-to-market operating model for Rare Diseases (Conditions). Lead role in the conceptualization, design, and then successful implementation of the new operating “infinity model” across Pharma International to enable accelerated entry and launch into two completely new disease areas for Roche - SMA and Huntingtons. As of 2022, Evrysdi is available to people with SMA conditions worldwide. Enabled by the new model, the launch is considered one of the most successful launches in rare conditions at Roche.

Led high-quality commercial assessment and input into Phase III planning and investment decisions, to ensure optimal value and access of our assets at launch in Europe. The role also extended to early strategic launch planning and support of franchise strategy development.

Selected to a CEC/BoD-sponsored task force to lead commercial strategy defending Roche's two highest-value brands, Herceptin and MabThera (combined annual sales >$10B), against the first wave of biosimilar monoclonal antibody competition. Key Achievement: Helped transform Roche's biosimilar posture from strategic uncertainty into a clearly defined readiness strategy that, within two years, was externally recognized as an industry benchmark, reshaping both internal positioning and market perception. Led the global commercial strategy and annual business plan to sustain and grow Herceptin and MabThera sales ahead of loss of exclusivity, and directed the International Business Team across EU, US, and top emerging markets to launch the subcutaneous formulations of both brands, a defining lifecycle play to ensure competitive resilience. Spearheaded and co-developed a new customer-facing resourcing model with Regional Franchise Leaders, rolled it out across Europe and the top 10 emerging markets, and owned the global product marketing budget of >CHF 30M.

Led the development and implementation of the Global Commercial Competitive Readiness Tactical Plan and supported the SC launch of Roche's highest value products: Herceptin and MabThera approximately $15B in combined global sales.

Responsible for sales activities of Herceptin (trastuzumab), Xeloda (capecitabine) and Avastin (bevacizumab) in breast cancer. First year in role exceed all sales targets and promoted to manage the high-value downtown Toronto territory and launch Zelboraf (vemurafenib) in Melanoma.

National position responsible for leading the annual strategic and tactical medical marketing plan development (during H1N1 2009 Global Pandemic). Managed the medical marketing activity budget and clinical trial budget ($3.8M) as well as supplier relationships. Led the strategic development and execution of a national advisory board. Advanced the brand strategy by recommending and seeing to fruition the publication of national treatment guidelines.

Product Manager for Tamiflu responsible for the annual tactical brand plan. Launched a new creative marketing campaign and marketing mix (sales force materials, training, account management plans, and congresses/symposia). Trained sales representatives by developing a creative training program that applied adult learning principles to identify needs, engage participants, and ensure learning was applied to day-to-day opportunities in the field.

Global Business School for Health Population Health Sciences The External Advisory Board is composed of senior leaders from industry, government, and academia who provide high-level strategic advice and sector insights. The board meets formally to review the direction and impact of GBSH in consultation with the Senior Management Team.

Member of the World Economic Forum’s Global Future Council on Leadership, advising on the next era of leadership and governance. Selected as part of 2025/2026 Global Future Council on Leadership. This group comprises leading thinkers, experts, government ministers, business leaders, international organizations, and civil society contributing to the debate, research and shaping of the future of leadership and sustainability.

Part of a global community of world leaders delivering impact who at the time of nomination, were under 40. Together, we dedicate time and energy to collaboratively shape a better future.

www.unlockingeve.org Unlocking Integrated Leadership for a Balanced and Healthier World, Paradigm-shifting research and tools—building the leadership teams of tomorrow and taking responsibility for our world today.

Strategy and Business Transformation, in Changing World. Patient Centric Operating Model (2021): https://www.utm.utoronto.ca/mbiotech/program-news/patient-and-customer-centricity-value-creation-changing-world-eva-mclellan-head Leadership Strategy in VUCA (2016): http://webcast.utm.utoronto.ca/1/Watch/1956.aspx Cutting through the noise, communication for impact https://prezentium.com/the-secret-sauce-to-inspirational-communication/

Responsible for business development and account management of over 100 clients, generating strategic leads, negotiating terms, and closed high-value contracts. Exceeded annual sales target by 40%, putting our division in the top rank.

Led a team of 3 associates conducting research experiments in neuropsychology focused on HPA axis development.

https://www.insead.edu/executive-education/general-management/transition-general-management

Graduate Class Representative MBSC Co-Founder Nominated for the Rotman MBA Venture Capital Competition MBiotech Alumni Profile Recipient MBiotech Industrial Inroads Recognition

I studied life science with a focus on two majors: Biochemistry and Neuroscience, graduating with academic distinction.